Related Experiment Video
Updated: Oct 4, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Cyclooxygenase-2 contributes to diabetic nephropathy through glomerular EP4 receptor
Yi Guan1, Linda Davis2, Matthew D Breyer3
1Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Abstract:
Diabetic nephropathy (DN) is a major microvascular complication of diabetes and the leading cause of mortality in diabetic patients. Cyclooxygenase (COX) and COX-derived prostanoids are documented to participate in the pathogenesis of diabetic nephropathy. Herein, we found an increased COX2 expression level in diabetic kidneys of STZ-induced DBA mice. The COX2 inhibitor significantly attenuated albuminuria and histological lesions, accompanied by up-regulation of the renal angiopoietin-1/tie-2 system. This finding is consistent with the presence of an angiogenic signature in endothelial cells during the development of DN. Prostaglandin E2 (PGE2) is the most abundant prostanoid in the kidney, and its receptor EP4 is expressed in the glomerulus, as determined by in situ hybridization. To test the hypothesis that diabetes-associated COX2 overexpression induces renal PGE2 production and endothelial dysfunction by activating glomerular EP4 receptors, the effect of an EP4 antagonist on Akita/DBA mice was investigated. Our results showed that blockade of EP4 receptor significantly reduced albuminuria in diabetic mice. Owing to the established adverse effect of COX2 inhibitors, our study provided new insight into meaningful renal benefits for diabetic nephropathy by targeting the EP4 receptor.
Insights
Diabetic nephropathy involves cyclooxygenase-2 (COX2). Targeting the EP4 receptor, not COX2, reduced kidney damage and albuminuria in diabetic mice, offering a safer therapeutic approach.
Area of Science:
- Nephrology
- Endocrinology
- Molecular Biology
Background:
- Diabetic nephropathy (DN) is a severe complication of diabetes, contributing to mortality.
- Cyclooxygenase (COX) and its products are implicated in DN pathogenesis.
- Increased COX2 expression is observed in diabetic kidneys.
Purpose of the Study:
- To investigate the role of COX2-derived prostanoids in DN.
- To test if EP4 receptor activation mediates DN-induced endothelial dysfunction.
- To evaluate EP4 receptor antagonism as a therapeutic strategy for DN.
Main Methods:
- Studied STZ-induced DBA and Akita/DBA mice models of diabetes.
- Administered COX2 inhibitors and EP4 antagonists.
- Assessed albuminuria, histological lesions, and renal angiopoietin-1/tie-2 system expression.
Main Results:
- COX2 inhibition reduced albuminuria and kidney damage, upregulating angiopoietin-1/tie-2.
- Prostaglandin E2 (PGE2) and its receptor EP4 are present in glomeruli.
- EP4 receptor blockade significantly decreased albuminuria in diabetic mice.
Conclusions:
- Diabetes-associated COX2 overexpression drives renal PGE2 production and endothelial dysfunction via glomerular EP4.
- EP4 receptor antagonism shows promise for treating diabetic nephropathy.
- Targeting EP4 offers a potentially safer alternative to COX2 inhibitors for DN treatment.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
cAMP-dependent Protein Kinase Pathways
GPCRs Regulate Adenylyl Cylase Activity
Cell Specific Gene Expression
Chronic Kidney Disease II: Clinical Manifestations